Dr. Maisa Feghali, MD
Claim this profileMagee Womens Hospital of UPMC
Studies Diabetes Mellitus
Studies Gestational Diabetes
5 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Maisa Feghali, MD is currently running
Exenatide
for Gestational Diabetes
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.
Recruiting3 awards Phase 44 criteria
Metformin vs Insulin
for Gestational Diabetes
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.
Recruiting3 awards Phase 42 criteria
More about Maisa Feghali, MD
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Maisa Feghali, MD has experience with
- Metformin
- Insulin
- Glyburide
- Exenatide
- Intensive Glycemic Targets
- Standard Glycemic Targets
Breakdown of trials Maisa Feghali, MD has run
Diabetes Mellitus
Gestational Diabetes
Cervical Dystocia
Pregnancies
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Maisa Feghali, MD specialize in?
Maisa Feghali, MD focuses on Diabetes Mellitus and Gestational Diabetes. In particular, much of their work with Diabetes Mellitus has involved treating patients, or patients who are undergoing treatment.
Is Maisa Feghali, MD currently recruiting for clinical trials?
Yes, Maisa Feghali, MD is currently recruiting for 3 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Maisa Feghali, MD has studied deeply?
Yes, Maisa Feghali, MD has studied treatments such as Metformin, Insulin, Glyburide.
What is the best way to schedule an appointment with Maisa Feghali, MD?
Apply for one of the trials that Maisa Feghali, MD is conducting.
What is the office address of Maisa Feghali, MD?
The office of Maisa Feghali, MD is located at: Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania 15213 United States. This is the address for their practice at the Magee Womens Hospital of UPMC.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.